What These Tests Measure and Best Lipid Parameter for Menopausal Women

For menopausal women, LDL-cholesterol (LDL-C) remains the primary recommended lipid parameter for cardiovascular risk assessment and treatment targets, though apolipoprotein B (apo B) and non-HDL-cholesterol provide valuable supplementary information when discordant with LDL-C. 1

Understanding the Tests

Apolipoprotein A (Apo A-I)

Apo A-I is the major protein component of HDL (high-density lipoprotein) particles and provides an estimate of HDL concentration 1
Each HDL particle carries multiple apo A-I molecules 1
Low levels are defined as <140 mg/dL for women, corresponding to low HDL-C 1
Postmenopausal women have the highest apo A-I concentrations compared to premenopausal women and men 2

Apolipoprotein B (Apo B)

Apo B represents the total number of atherogenic lipoprotein particles in circulation, including VLDL, IDL, and LDL 1
Each atherogenic particle contains exactly one apo B molecule, making it a direct measure of particle number 3
Apo B is particularly useful when small dense LDL particles are elevated, as it captures total atherogenic burden better than LDL-C alone 1
The test does not require fasting and is not affected by moderately elevated triglycerides 1

Small Dense LDL-Cholesterol (sdLDL-C)

sdLDL-C measures a specific subclass of LDL particles that are smaller and denser than typical LDL 1
These particles are more atherogenic than larger, more buoyant LDL particles 4
High triglycerides are often associated with elevated levels of small dense LDL 1
Currently considered an "emerging risk factor" but not recommended for routine risk estimation 1

Specific Considerations for Menopausal Women

Impact of Menopause on Lipid Parameters

Menopause significantly affects lipid profiles, with distinct patterns across different markers:

Total cholesterol increases by approximately 10% after menopause 5
LDL-C rises by 14% and apo B increases by 8.2% within 3 years of menopause onset 5
Apo B concentrations in women rise with age and menopause to converge with male levels around age 50-55 years 2
Menopausal status is associated with higher concentrations of both sdLDL-C and sdLDL-apoB 6
The LDL-C/apo B ratio is generally higher in women than men, indicating larger LDL particles 2
Postmenopausal women have decreased cholesterol content per HDL particle (lower HDL-C/apo A-I ratios), approaching the unfavorable ratios seen in men 2

Which Parameter is Best?

The evidence strongly supports LDL-C as the primary target, with specific caveats:

Primary Recommendation: LDL-Cholesterol

LDL-C remains the primary target recommended by major guidelines because most risk estimation systems and virtually all clinical trials demonstrating cardiovascular benefit are based on LDL-C 1
Multiple clinical trials have established that LDL-C reduction is associated with statistically and clinically significant reduction in cardiovascular mortality 1
LDL-C is supported by the strongest evidence base for treatment targets 1

When to Consider Apo B

Apo B provides superior risk assessment in specific circumstances relevant to menopausal women:

When apo B and LDL-C are discordant, cardiovascular risk aligns better with apo B 7, 8
Even 2% discordance between apo B and LDL-C is associated with elevated cardiovascular risk 7
Apo B is particularly valuable in women with metabolic syndrome, diabetes, or elevated triglycerides—conditions more common after menopause 1, 9
Post-hoc analyses suggest apo B may be a better treatment target than LDL-C, though it hasn't been evaluated as a primary endpoint in trials 1
Apo B ≥130 mg/dL should be considered a risk-enhancing factor 10

Role of Non-HDL-Cholesterol

Non-HDL-C (calculated as total cholesterol minus HDL-C) provides similar information to apo B and is easily obtained from a standard lipid panel 1
Non-HDL-C can provide better risk estimation than LDL-C, particularly with elevated triglycerides, diabetes, or metabolic syndrome 1
Non-HDL-C >190 mg/dL should be considered a risk-enhancing factor 10

Limited Role for sdLDL-C

sdLDL-C measurement is not currently recommended for routine risk estimation 1
It may be regarded as an emerging risk factor for future use but lacks sufficient evidence for clinical decision-making 1
The 2010 ACC/AHA guidelines explicitly state that measurement of lipoprotein particle size beyond standard lipid profiles is not recommended 3

Practical Clinical Algorithm for Menopausal Women

Follow this stepwise approach:

Obtain a standard fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides) as the foundation 1
Calculate non-HDL-C (total cholesterol - HDL-C) from the standard panel 1
Consider measuring apo B if any of the following are present:
- Metabolic syndrome 1, 9
- Type 2 diabetes 1
- Triglycerides >200 mg/dL 1, 9
- Discordance between calculated LDL-C and clinical risk 8
- Family history of premature cardiovascular disease 8
Use LDL-C as the primary treatment target, with apo B or non-HDL-C as secondary targets when measured 1
Do not routinely measure sdLDL-C for risk assessment 1, 3

Important Caveats

Be aware of these common pitfalls:

The apo B/apo A-I ratio provides risk estimation but components should be considered separately for treatment targets 1
While apo B may be superior for risk prediction, it is not included in standard risk algorithms and has not been a predefined treatment target in controlled trials 1
Apo B does not provide benefit beyond non-HDL-C in some populations (e.g., diabetes patients in the FIELD study), though other meta-analyses show superiority 1
The evidence for raising HDL-C (or apo A-I) to reduce cardiovascular events is weak compared to lowering LDL-C (or apo B) 11
Postmenopausal women experience unfavorable changes in both atherogenic particles (increased apo B) and HDL quality (decreased cholesterol per particle), making comprehensive lipid assessment particularly important 2, 5

What do apolipoprotein A, apolipoprotein B, and small‑dense LDL‑cholesterol tests measure, and which is the most useful lipid marker for a menopausal woman?

Have a follow-up question?